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Multidrug-resistant tuberculosis (MDR-TB) is a growing problem worldwide.
Hypothyroidism is a known complication of treatment with para-aminosalicylic acid (PAS),
ethionamide (ETH) or prothionamide (PTH), all of which are typically included in treatment
of MDR-TB.1–4 Although hypothyroidism is known to be associated with MDR-TB
treatment, the magnitude of the problem remains unclear. A recent study published by Satti
et al. reported a hypothyroid-ism prevalence of 69% in a cohort of 186 patients in Lesotho.5
As this is higher than the prevalence reported in most other cohorts, the authors left the
question open as to whether this was a unique phenomenon of their cohort or whether their
findings could indicate an underreported problem. Here, we report our experience with
regard to hypothyroidism among patients treated for MDR-TB in Botswana.
We have been prospectively following all MDR-TB patients in Botswana since January
2007. For the purpose of this report, we used the definition of hypothyroidism used by Satti
et al., i.e., thyroid stimulating hormone (TSH) > 10.0 μIU/l.5 Screening for hypothyroidism
among patients on MDR-TB treatment is recommended by national guidelines, but thyroid
function tests are ordered at the discretion of the managing clinician. Of 452 patients
included in the analysis, 213 (47.1%) had their TSH levels checked at some point in their
treatment: 73 (16.2% of the cohort and 34.3% of those with TSH levels checked) were found
to have evidence of hypothyroidism. The median time from initiation of MDR-TB treatment
to hypothyroidism was 260 days (range 132–365). Other characteristics of the cohort are
shown in the Table.
We conducted multivariate logistic regression to identify potential factors associated with
the development of hypothyroidism, an independent analysis of the entire cohort and an
analysis of those patients who had their TSH levels checked. The model included sex, age,
human immunodeficiency virus (HIV) status, use of PAS, ETH, time on treatment, culture
conversion at 6 months and outcome. As PTH is not available in Botswana, none of the
patients were receiving this drug. Male sex was the only variable associated with the
development of hypothyroidism (adjusted odds ratio 2.5, 95% confidence interval 1.4–4.4).
Our MDR-TB cohort is one of the largest to be studied prospectively for hypothyroidism.
Our results support the findings reported by Satti et al., and suggest that hypothyroidism
may be an important, yet under recognised problem among patients being treated for MDRTB.5 To our knowledge, the association between male sex and the development of
hypothyroidism on MDR-TB treatment has not been reported previously. The reason for this
association is unclear, and may be related to methodological issues intrinsic to the design of
the study. Nevertheless, our experience, together with that of other authors, highlights the
need for better designed prospective studies.
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Table

Clinical characteristics of MDR-TB patients: screening for and diagnosis of hypothyroidism
All patients (n = 452)
median [IQR] or n (%)

Patients with TSH levels checked (n = 213)
median [IQR] or n (%)

Patients diagnosed with hypothyroidism (n =
73)
median [IQR] or n (%)

Age, years

37 [28–48]

38 [28–48]

40 [28–49]

Male sex

249 (55.1)

140 (65.7)

53 (72.6)

On PAS

33 (7.3)

16 (7.5)

5 (6.8)

On ETH

85 (18.8)

49 (23.0)

14 (19.2)

HIV-infected

289 (63.4)

135 (63.4)

49 (67.1)

240 [129–372]

241 [126–413]

239 [138–370]

269 (93.1)

130 (96.3)

47 (95.9)

CD4 cells/mm3
On ART

MDR-TB = multidrug-resistant tuberculosis; TSH = thyroid stimulating hormone; IQR = interquartile range; PAS = para-aminosalicylic acid; ETH
= ethionamide; HIV = human immunodeficiency virus; ART = antiretroviral therapy.
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